12 November 2018

AMRA’s White Paper Now Available, Sharing Insights on Body Composition Profiling in Clinical Trials

AMRA’s White Paper Now Available, Sharing Insights on Body Composition Profiling in Clinical Trials

Linköping, Sweden [November 12, 2018] AMRA has now published a White Paper providing insights about the link between specific fat distributions and metabolic diseases. Body composition and fat distribution is an unknown factor in many clinical trials conducted in the metabolic area today. Many studies are likely conducted in a population thought to be homogeneous, while those studies actually include subjects with vastly different body compositions associated with completely different metabolic disease profiles. The answer to whom should be included and which subjects respond best to a treatment could lie in body composition.

Click here to read the White Paper

 

 

AMRA is a ground-breaking international digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition assessment, the ability to automatically produce multiple fat and muscle biomarkers with unrivaled precision and accuracy, as well as contextual disease insights – all from a single, rapid, whole-body MRI.

Contact

Rosemary Shull
SVP Global Business Development & Marketing
rosemary.shull@amramedical.com

comment

Latest News

language

Meet Us Here

13th International SCWD Digital Conference on Cachexia, Sarcopenia and Muscle Wasting

date_range 11 December 2020 - 13 December 2020
account_boxSet Up a Meeting